Oxford GlycoSciences Plc has received notice from the European Patent Office that it intends to grant OGS a patent covering the fundamental platform technology it has developed for use in conducting proteomics research.

The patent gives OGS proprietary rights to computer-assisted methods and apparatus for identifying and isolating biomolecules in a biological sample. The patent is expected to be granted in Q1 2003. Corresponding patents have already been granted to OGS in the US.

David Ebsworth, CEO of OGS said, "This patent is an affirmation that OGS is at the forefront of innovation and excellence in proteomics research. It also presents the opportunity for additional revenue through licensing to pharmaceutical and other companies which utilize processes we have developed in their proteomics research."